Lady Prelox® improves sexual function in generally healthy women of reproductive age.
OBJECTIVE
This supplement study evaluates the Female Sexual Function Index (FSFI) of 100 healthy women (37 to 45 years) with moderate sexual dysfunction who underwent a management program of lifestyle, diet, exercise, and stress control. In association with the management program a group of these women also used the supplement Lady Prelox® in tablets (20 mg Pycnogenol® pine bark extract, 200 mg L-arginine, 200 mg L-citrulline and 50 mg Rosvita® rose hip extract) for eight weeks.


METHODS
One group of women was supplemented with Lady Prelox® for 8 weeks. The nine-item FSFI questionnaire was used for evaluation of women's sexual function at inclusion (baseline), after four weeks, and after eight weeks of management and supplementation. Variation in oxidative stress was also evaluated by measuring plasma free radicals.


RESULTS
Following supplementation with Lady Prelox® the mean total FSFI scores increased from 14.96±2.68 to 28.25±2.35 after four weeks and 33.91±2.7 after eight weeks. Treatment values were significantly higher than in controls (who used only the management plan) with baseline values of 17.92±2.32 and scores of 23.45±1.82 after four weeks and to 23.52±2.20 after eight weeks. Women in the Lady Prelox® group had an initial value of plasma free radicals (PFR) of 398±29 Carr units: this value decreased to 344:28 at 4 weeks (P<0.05) and 332:31 at 8 weeks (P<0.05). Lower changes were observed in controls with an initial value of 389±33, decreasing to 377±32 (P<0.05) at 4 weeks and to 365; 33 (P<0.05) at 8 weeks (value significantly higher in controls not using Lady Prelox®). The supplementation was well tolerated; no unwanted effects occurred and no women had to stop the supplementation.


CONCLUSIONS
The study suggests that supplementation with Lady Prelox significantly improves sexual function across all domains evaluated by the FSFI in healthy women of late reproductive age. The improvement in FSFI is also associated with a significant decrease in oxidative stress.
Irvine 3 Circulation, Vascular Labs Department of Biomedical Sciences Chieti-Pescara University, SS 16 bis 94 (A), Spoltore, Pescara, Italy - cardres@abol.it.
A
A
Bottari
G
G
Belcaro
A
A
Ledda
R
R
Luzzi
M R
MR
Cesarone
M
M
Dugall
D000328:Adult; D000975:Antioxidants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001120:Arginine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002956:Citrulline / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019587:Dietary Supplements / Q000009:adverse effects; D004414:Dyspareunia / Q000188:drug therapy; D005260:Female; D005419:Flavonoids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005609:Free Radicals / Q000097:blood; D006801:Humans; D007989:Libido / Q000187:drug effects; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D011795:Surveys and Questionnaires
D000975:Antioxidants; D005419:Flavonoids; D005609:Free Radicals; C584912:Lady Prelox; D002956:Citrulline; D001120:Arginine